Nasdaq rxrx - Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The fund owned 2,335,132 shares of the company's stock after selling …

 
Wood added to existing positions in Roku (NASDAQ: ROKU), Recursion Pharmaceuticals (NASDAQ: RXRX), and Rocket Lab USA (NASDAQ: RKLB) on Tuesday. Let's take a closer look. 1. Roku.. Turbanli por

Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 320.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The institutional investor owned 3,523,124 shares of the company's stock …Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past yearJul 13, 2023 · Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing.This ... Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages ...That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for …In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has announced the signing of agreements to acquire Cyclica and Valence, two companies with expertise in AI-enabled drug discovery.These acquisitions strengthen Recursion's position in computational chemistry, machine learning, and artificial …Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues Dec 09. Co-Founder notifies of intention to sell stock Dec 08. Chief Financial Officer exercised options and sold US$266k worth of stock Nov 19. Consensus EPS estimates fall by 18% Nov 16.See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. The stock price for . Recursion Pharmaceuticals (NASDAQ: RXRX) is $9.98 last updated Today at January 18, 2024 at 7:59 PM EST. Q Does Recursion …Stock. Equities. Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ): Stock quote, stock chart, quotes, analysis, …REC-2282 is developed for the treatment of neurofibromatosis type 2. paper trading platform. Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart.Recursion Pharmaceuticals ( RXRX -2.00%) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 320.7% in the third quarter, according to the company in its most recent ...Jul 18, 2023 · After announcing that it would get a $50 million investment from NVIDIA (NVDA 0.27%) on July 12, Recursion Pharmaceuticals (RXRX 8.83%) saw its stock blast off, rising 87% over the following two ... That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for …Stocks RXRX Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future December 14, 2023 — 02:31 pm EST Written by Sushree Mohanty …Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ...iLexx. Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week.This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and ...Earnings Trend: RXRX is unprofitable, and losses have increased over the past 5 years at a rate of 36% per year. Accelerating Growth: Unable to compare RXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable. Earnings vs Industry: RXRX is unprofitable, making it difficult to compare its past year earnings ...Stocks RXRX Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future December 14, 2023 — 02:31 pm EST Written by Sushree Mohanty …The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31 ...Nasdaq. 15,415.02 +104.05 (+0.68%) ... Investors in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have tasted that bitter downside in the last year, as the share price dropped 20%. That's ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...2 days ago · Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ... Jul 6, 2023 · Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ... Nasdaq Futures 17,538.50 +100.00(+0.57%) Russell 2000 Futures 1,961.90 +7.10(+0.36%) Crude Oil 73.13 -0.28(-0.38%) Gold 2,023.30 -6.00(-0.30%) Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS -... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States.The US$14.13 analyst price target for RXRX is 3.5% less than our estimate of fair value Does the July share price for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) reflect what it's really worth?Jan 17, 2024 · Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media. Current. In recent news, Recursion (NASDAQ: RXRX), a prominent clinical stage TechBio firm, has announced the signing of agreements to acquire Cyclica and Valence, two companies with expertise in AI-enabled drug discovery.These acquisitions strengthen Recursion's position in computational chemistry, machine learning, and artificial …Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company that combines the disciplines of biology, chemistry, data analytics, and engineering to develop drugs.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages ...Oct 14, 2021 · The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ... 2 days ago · Mirae Asset Global Investments Co. Ltd. increased its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 31.0% in the 3rd quarter, according to the company in ... The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...Jan 21, 2024 · Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,335,132 shares of the compa Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...Nov 26, 2023 · For a biotech like Recursion Pharmaceuticals (RXRX-2.63%) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ... Nov 21, 2023 · Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-3.13%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ... Jan 17, 2024 · Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media. Current. Shares of Recursion Pharmaceuticals (RXRX-2.63%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.1 day ago · The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last year, but it's still early innings for ... Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities).The average one-year price target for Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) has been revised to 17.17 / share. This is an increase of 7.12% from the prior estimate of 16.03 dated August 31 ...4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...AMD. Advanced Micro Devices, Inc. Common Stock. $177.25 -3.08 -1.71%. Get the latest updates on Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) after hours trades, after hours share ... Jul 14, 2023 · Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ... Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company that combines the disciplines of biology, chemistry, data analytics, and engineering to develop drugs.Dec 14, 2023 · Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ... See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. With a relentless focus on transforming the biotechnology landscape through its artificial intelligence (AI) and machine learning (ML) driven platform, Recursion Pharmaceuticals (NASDAQ:RXRX ...The US$14.13 analyst price target for RXRX is 3.5% less than our estimate of fair value Does the July share price for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) reflect what it's really worth?Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year.NVIDIA Corporation Common Stock. $450.47 +0.42 +0.09%. MSFT. Microsoft Corporation Common Stock. $352.60 -0.20 -0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours ...Dec 14, 2023 · Clinical-stage biotech companies often take time to be profitable. Recursion's total revenue in Q3 dipped to $10.5 million compared to $13.2 million in Q3 2022. Its net loss in the quarter came in ... Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ...Key statistics. On Friday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 11.16, -33.35% below its 52-week high of 16.75, set on Jul 19, 2023. Data delayed at least 15 minutes, as of Jan 12 2024 21:00 GMT. Latest Recursion Pharmaceuticals Inc (RXRX:NSQ) share price with interactive charts, historical prices, comparative analysis, …2 days ago · Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ... Recursion Pharmaceuticals (RXRX) Insider Trading & Ownership. $10.26. -0.50 (-4.65%) (As of 01/17/2024 ET) Stock Analysis Analyst Forecasts Chart Competitors …Recursion Pharmaceuticals Stock Down 2.6 %. Shares of NASDAQ RXRX opened at $9.63 on Monday. The business has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of ...Over the past 3 months, she has purchased 1,900,644 RXRX shares via her ARKG ETF, and her overall holdings now stands at 6,192,719 shares. ... The Nasdaq Composite still hasn't recouped all of its ...Recursion Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View RXRX financial statements in full.Clinical-stage biotech company Recursion Pharmaceuticals (NASDAQ:RXRX) might be a relatively small company, but it’s taking significant steps toward a stronger future. Wall Street currently ...NVIDIA Corp $593.90 NVDA0.44% Archer Aviation Inc $5.50 ACHR3.48% Marinus Pharmaceuticals Inc $10.19 MRNS0.69% Tesla Inc $212.53 TSLA1.79% Palantir …Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Jan 19, 2024 · A. The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Wednesday, January 17, 2024. The analyst firm set a price target for 15.00 expecting RXRX to ... Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...RECURSION PHARMACEUTICALS INC ( RXRX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 43% based on the firm’s underlying fundamentals and the ...SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S ...Recursion Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View RXRX financial statements in full.Recursion Pharmaceuticals ( RXRX -2.00%) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...Stocks RXRX Recursion Pharmaceuticals Stock (NASDAQ:RXRX): Small Company, Big Future December 14, 2023 — 02:31 pm EST Written by Sushree Mohanty …Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues Dec 09. Co-Founder notifies of intention to sell stock Dec 08. Chief Financial Officer exercised options and sold US$266k worth of stock Nov 19. Consensus EPS estimates fall by 18% Nov 16.Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.

See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.. Gene

nasdaq rxrx

That's what's happening with Recursion Pharmaceuticals ( RXRX -4.40%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...Welcome to Recursion: The Future of TechBio LEARN HOW › NEWS: Recursion unveils LOWE, an LLM-Orchestrated Workflow Engine for drug discovery Decoding Biology To …Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a $1.7bn biopharma company which uses the Recursion OS, or Operating System, methods that it claims makes the drug discovery process more efficient.Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ...On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals ( RXRX 4.83%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... 3. Its services segment has yet to prove its value. Recursion has three segments: Its pipeline, discovery collaborations, and software licensing. Its pipeline projects are still early-stage, so ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages ...Overview Financials News Ideas Technicals Forecast RXRX chart Today −3.58% 5 days −13.64% 1 month 12.08% 6 months −29.95% Year to date 11.16% 1 year 25.41% 5 years …Recursion Pharmaceuticals Stock Down 2.6 %. Shares of NASDAQ RXRX opened at $9.63 on Monday. The business has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Key statistics. On Friday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 11.16, -33.35% below its 52-week high of 16.75, set on Jul 19, 2023. Data delayed at least 15 minutes, as of Jan 12 2024 21:00 GMT. Latest Recursion Pharmaceuticals Inc (RXRX:NSQ) share price with interactive charts, historical prices, comparative analysis, …Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ... Although the biotech company missed revenue consensus, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw a 150% increase in revenue in the third quarter to $2.5 million in Q3 2021, up from $1 ...Health Care Sector Update for 01/04/2024: SEM, XERS, RXRX, OMGA, NVO January 04, 2024 — 03:53 pm EST Written by MT Newswires for MTNewswires ->GuruFocus Research January 25, 2024 at 8:52 PM · 2 min read Director Blake Borgeson of Recursion Pharmaceuticals Inc ( NASDAQ:RXRX) has sold 20,054 shares …2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...That means RXRX is a top biotech stock capturing the overall trend rather than betting the farm on a single drug or therapeutic. And major players are taking note. Nvidia (NASDAQ: NVDA) is betting ....

Popular Topics